June 29, 2021
SPTR, CMS Final Rule & VA Public Law Updates
5 Minute Read
The latest regulatory updates and reporting reminders for June 2021.
Blog
June 17, 2021
Operational Goals to Future Proof Market Access
3 Minute Read
In this third installment, we look at operational goals for Market Access. Commercial Operations and Contracting teams need a flexible infrastructure that can support business scale and the changing...
June 14, 2021
Frequently Asked Questions – Patient Tokenization
3 Minute Read
Patient tokenization is one of the most mysterious, least understood, and most essential technologies behind actionable patient data. Taken from the Q&A session of IntegriChain's recent Patient Tokenization webinar....
June 3, 2021
Financial Goals to Future Proof Market Access
3 Minute Read
In this four-part series, we examine the key goals of Market Access teams as they look to the future with the advent of speciality and precision medicine and how...
May 27, 2021
Making Sense of Co-Pay Offset Programs
4 Minute Read
We dive into the specifics of co-pay offset programs and also examine updates to 340B administrative dispute resolution and ASP reporting as per H.R. 133.
May 20, 2021
Future Proofing Market Access with a Unified Data and Technology Platform
4 Minute Read
This is the first of a series examining the commercial, financial, and operational goals of Market Access, which are all are stymied by data and application silos.
April 21, 2021
Updates to State Price Transparency Reporting, Medicaid Laws
3 Minute Read
Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
April 14, 2021
The Current State of Pharmaceutical Price Transparency Reporting
2 Minute Read
What you need to know about navigating a patchwork of state policies, achieving operational readiness, and avoiding compliance risk.
March 11, 2021
Changes to Medicare Part D, Drug Rebate Program, OIG Final Rule
5 Minute Read
Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.